← Back to Search

Behavioral Intervention

Digital Therapeutics for Depression

N/A
Waitlist Available
Led By Lauren Oberlin, PhD
Research Sponsored by AdventHealth
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, mid-treatment (week 2), and post-treatment (week 4)
Awards & highlights
No Placebo-Only Group

Summary

This trial tests a digital brain training program for older adults with depression-related apathy. The program is expected to improve brain connections and reduce apathy symptoms by enhancing cognitive control.

Who is the study for?
This trial is for people over 60 with major depressive disorder and significant apathy, but no psychotic features. They must have a certain level of depression severity, be stable on antidepressants or other psychotropic meds for at least 8 weeks, and not plan to change doses soon. Participants need computer access, can follow instructions in English, are able to undergo MRI scans (no metal implants), and aren't at suicide risk or have serious medical/neurological conditions.
What is being tested?
The study tests whether a custom digital cognitive training program can improve brain function related to apathy in older adults with depression. Over four weeks, participants will use this program aiming to reduce symptoms of apathy as well as enhance cognitive control performance.
What are the potential side effects?
Since the interventions involve non-invasive digital cognitive exercises rather than medication or invasive procedures, side effects may include eye strain or headache from screen time; however specific side effects are not detailed in the provided information.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, mid-treatment (week 2), and post-treatment (week 4)
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, mid-treatment (week 2), and post-treatment (week 4) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Resting State Functional Connectivity among the Salience, Executive Control, and Reward Networks
Secondary study objectives
Change in Apathy Evaluation Scale (AES) score
Change in Stroop Interference score

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Targeted Cognitive Training InterventionExperimental Treatment1 Intervention
Group II: General Cognitive Training InterventionActive Control1 Intervention

Find a Location

Who is running the clinical trial?

AdventHealthLead Sponsor
115 Previous Clinical Trials
31,281 Total Patients Enrolled
National Institute of Mental Health (NIMH)NIH
2,910 Previous Clinical Trials
2,738,926 Total Patients Enrolled
1 Trials studying Apathy
22 Patients Enrolled for Apathy
Weill Medical College of Cornell UniversityLead Sponsor
1,084 Previous Clinical Trials
1,138,794 Total Patients Enrolled

Media Library

Targeted Cognitive Training Intervention (Behavioral Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05877885 — N/A
Apathy Research Study Groups: Targeted Cognitive Training Intervention, General Cognitive Training Intervention
Apathy Clinical Trial 2023: Targeted Cognitive Training Intervention Highlights & Side Effects. Trial Name: NCT05877885 — N/A
Targeted Cognitive Training Intervention (Behavioral Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05877885 — N/A
~56 spots leftby Nov 2029